ECONOMIC ANALYSIS OF ENZYMATIC DEBRIDEMENT VERSUS STANDARD BURN CARE: A RETROSPECTIVE ANALYSIS.

When compared to standard surgical management, rapid enzymatic debridement of deep burns reduces the need for surgery while achieving similar long-term results. However, few studies have directly compared the costs of standard surgical and enzymatic burn care. We conducted a study comparing the care costs of 44 adult burn patients treated before (n=22) and after (n=22) introducing rapid bromelain-based enzymatic debridement (BED) of deep burns. Mean age was 59 years, 54% were male, and mean total body surface area (TBSA) was 23.5%. Burn etiology included flame and scalding burns (8). Groups treated with standard of care and enzymatic debridement were comparable in terms of age, sex and TBSA. Burn management with BED significantly reduced total debridement costs as well as grand total costs when compared with traditional surgical care. Such reduction was mostly related to lower costs associated with reduced surgical care and less facilities and resources consumption in the BED group.

Comparativement au traitement standard, l'excision enzymatique précoce (EEP) réduit la nécessité de chirurgie, à résultats égaux à long termes. Très peu d'études ont comparé les coûts de ces deux stratégies. Nous avons comparé 2 groupes de 22 patients profondément brûlés ayant pour l'un été pris en charge conventionnellement, l'autre ayant bénéficié d'une EEP. L'âge moyen était de 59 ans, 54% étaient des hommes, la surface brûlée moyenne de 23,5% (les 2 groupes étaient comparables). Seuls 8 patients avaient été ébouillantés, les autres étant brûlés par flamme. L'utilisation d'EEP réduisait significativement le coût de la prise en charge, en rapport avec la réduction de l'utilisation de locaux et de matériel consécutifs à la chirurgie.

Réplica a «Pápulas faciales en alopecia frontal fibrosante con buena respuesta a isotretinoína» / Reply to «Facial Papules in Frontal Fibrosing Alopecia: Good Response to Isotretinoin»

No disponible

Postmastectomy upper limb lymphedema: Combined vascularized lymph node transfer and scar release with fat graft expedites surgical and patients' related outcomes. A retrospective comparative study.

INTRODUCTION: Lymphedema resulting from breast cancer treatment is a chronic condition that can significantly compromise quality of life. Several works have documented the efficacy of vascularized lymph node flap transfer (VLNT) for the treatment of advanced-stage lymphedema. Given that the axillary scar may contribute to the patient's existing lymphedema, the authors assumed that combining VLNT and scar release with fat graft could be an effective strategy of treatment. The purpose of this study is to compare the efficacy in the reduction of limb circumference and health-related quality of life between a combined strategy, namely, VLN transfer (VLNT) and axillary scar release with fat grafting, and only VLNT for patients affected by postmastectomy upper limb lymphedema. The idea. MATERIALS AND METHODS: All patients with stage II and III breast cancer-related lymphedema operated between January 2012 and January 2016 were retrospectively identified, and only those treated by combined VLNT and scar release (Group A) or only VLNT (Group B) were included. The outcomes were assessed clinically by limb circumference measurement and radiologically by lymphoscintigraphy. Lymphedema-related quality of life was evaluated preoperatively and at 1 year follow-up through the LYMQOL questionnaire. RESULTS: Thirty-nine patients met inclusion criteria (Group A = 18; Group B = 21). Mean follow-up was 29 months for Group A and 32 months for Group B. Flap survival rate was 100%, with no donor site morbidity in all patients. A statistically significant difference between the circumference reduction rates (RR) at above elbow level was observed at 3 and 6 months of follow-up comparing the two groups (p<0.00001), with higher values in Group A than in Group B. No significant difference was detected comparing RR values at above and below elbow at 12 and 24 months postoperatively. LYMQOL metrics showed significantly better scores (p<0.0001) in all domains at all follow-up appointments in Group A. CONCLUSIONS: Patients with postmastectomy upper limb lymphedema can benefit from combined lymph node transfer and axillary scar release with fat graft, as this approach seems to fasten the onset of improvement and to have a positive impact on patients' quality of life.

Letter to editor: Surgical-site infection following lymph node excision indicates susceptibility for lymphedema: A retrospective cohort study of malignant melanoma patients.

Following the reading of the original article "Surgical-site infection following lymph node excision indicates susceptibility for lymphedema: A retrospective cohort study of malignant melanoma patients", the authors reviewed the literature for the discussed therapeutic value of complete lymph node dissection (CLND), the major complications and the current treatment for lymphedema. The authors also share their experience and protocol for CLND, and treating lymphedema using lymph node flap transfer and multiple lymphatic-venous anastomoses.

Robotic inguinal lymph node dissection for melanoma: a novel approach to a complicated problem.

Following the interesting reading of the article "Robotic inguinal lymph node dissection for melanoma: a novel approach to a complicated problem", the authors review the pros and cons of a minimally invasive technique for lymph node dissection, the consequences of complete lymph node dissection and the possible treatments for lymphedema, such as lymph node flap transfer and multiple lymphatic-venous anastomoses. The authors also review the possible benefits of applying the robotic technique to anatomical sites other than the inguinal one.

The use of Nexobridtm in debriding chronic ulcers: a preliminary observational study.

Nexobrid is a highly selective enzymatic debriding agent used in the acute management of burns to perform escharectomy. From October 2016 to April 2017, we treated 6 patients affected with lower limb chronic ulcers of different etiologies with Nexobrid in order to perform eschar removal by enzymatic debridement. For all patients, a dosage of Nexobrid, calculated as 2gr per 1% TBSA, was applied in a 2-3 mm thick uniform layer on the ulcer eschar and fibrin tissue and left for 4 hours, covered with an occlusive dressing. Patients were assessed in terms of ulcer cleansing 24 hours and 7 days post Nexobrid debridement, by wound bed score (WBS) and % of remaining necrotic tissue. A patient pain VAS was also recorded at 24 hours and 7 days post debridement. Adverse events at these time points were also noted. The results documented a complete removal of necrotic tissue in a time frame of 4 hours. At 24 hours, all lesions were completely debrided. At 7 days, there was a partial recurrence of necrotic tissue, as also documented by decreased WBS. All patients reported none to mild pain, and no adverse events were noted, except for mild erythema along the edges of the lesion on healthy skin in one case. This is a preliminary observation. Optimal dosage and application of Nexobrid in this indication needs to be validated by further controlled data.

Nexobrid est un agent de débridement hautement sélectif utilisé dans la prise en charge des brûlés pour réaliser une excision enzymatique. Entre octobre 2016 et avril 2017, nous l'avons utilisé pour réaliser ce même type d'excision chez 6 patients souffrant d'ulcères chroniques de jambe, d'étiologies variées. Nous avons appliqué 2g de Nexobrid par % de surface coporelle atteinte, en une couche uniforme de 2-3 mm d'épaisseur laissée en place 4h sous pansement occlusif. À 24 h et 7 jours, nous avons évalué le score de fond de plaie (Wound Bed Score-WBS), le pourcentage restant de tissu nécrotique, la douleur (EVA) et les effets secondaires. À 4h, les tissus nécrosés avaient entièrement disparu, ne réapparaissant pas à 24 h. À J7, on notait une réapparition, sur une surface moindre, de tissus nécroiques et une altération du WBS. Les patients étaient non ou peu douloureux. Le seul effet secondaire observé, chez un patient, a été un érythème modéré de la peau saine circonscrivant la lésion. À la suite de cette étude préliminaire, des études plus larges permettront de préciser les modalités d'utilisation de Nexobrid dans cette indication.

Mancha de vino de Oporto adquirida: no es una simple mancha / Acquired Port-Wine Stain: Not a simple stain

No disponible

Spontaneous healing and scar control following enzymatic debridement of deep second-degree burns.

Scarring after a burn injury remains the greatest unmet challenge in the treatment of functional and psychosocial sequelae of burns. The hypertrophic scar represents the most common type of cicatrix after burns, and it has a prevalence of up to 70%. We present a case of upper and lower extremity partial-thickness burns in a female patient treated in two different modalities. Superficial seconddegree burns on the upper extremities were treated with conservative dressing with fairly early wound closure but they developed hypertrophic scars. Deeper, lower extremity burns were debrided with a new bromelain-based debriding agent, resulting in scar-free healing. The pathophysiology of hypertrophic scar formation is based on the perturbation of collagen production or degradation or both. The duration and magnitude of the inflammatory phase of wound healing also appears to play a role in hypertrophic scarring. Bromelain has demonstrated an anti-angiogenic effect in various cancer cell lines and it has been shown to regulate a variety of pro-angiogenic growth factors. This case raises the classical question of the relationship between time to healing and formation of hypertrophic scars after burn injury, pointing to other potential factors that may play an important role in burn healing.

La cicatrisation après une brûlure reste le plus grand défi du traitement des séquelles à la fois sur le plan fonctionnel et sur le plan psychologique. La cicatrisation hypertrophique représente l'évolution la plus fréquente après brûlure et sa prévalence est supérieure à 70 %. Nous présentons une observation de brûlures du 2e degré au niveau du membre supérieur et du membre inférieur chez une patiente traitée suivant deux modalités différentes. Les brûlures du second degré superficiel du membre supérieur furent traitées par un pansement classique avec une cicatrisation précoce, mais suivie de cicatrices hypertrophiques. Les brûlures plus profondes du membre inférieur furent détergées avec le nouvel agent à base de bromelaïne, et permirent une guérison sans cicatrice. La physiopathologie de la cicatrisation hypertrophique est basée sur les troubles de production des fibres de collagène, ou de leur dégradation, ou des deux. La durée et l'amplitude de la phase inflammatoire de la cicatrisation paraît aussi jouer un rôle dans l'hypertrophie cicatricielle. La bromelaïne a démontré son effet anti-angiogénique dans plusieurs lignées cellulaires cancéreuses ; elle a montré aussi son aptitude à réguler les divers facteurs de croissance pro-angiogéniques. Cette observation soulève la question classique de la relation entre le temps de cicatrisation et l'apparition de cicatrices hypertrophiques après brûlure, en soulignant les autres facteurs potentiels jouant un rôle important dans la cicatrisation des brûlures.

Unusual presentation of carpal tunnel syndrome with cutaneous signs: a case report and review of the literature.

Carpal tunnel syndrome (CTS) is a neurological impairment caused by compression of the median nerve throughout the carpal tunnel, which consequently induces ischemia and mechanical disruption, dysfunctional axonal transport, and epidural blood flow. Most common symptoms include numbness, rather than pain, with a typical night exacerbation, weakness, paresthesia, and loss of sensitive discrimination. In rare cases, such syndrome may present with cutaneous manifestations localized on the distal phalanges of the hands, even without the above mentioned neurological symptoms. We describe a case of a woman who came to our attention complaining of the appearance of recurrent bullous eruptions involving the distal phalanges innervated by the median nerve. She did not report any neurological signs whatsoever. After excluding a bullous disease, we further investigated through additional analysis that revealed a CTS. Hence, physicians should consider CTS as a differential diagnosis when assessing cutaneous lesions of the first three fingers of the hands.